CollPlant discontinues regenerative medicine research

The cost-reduction plan discontinues regenerative medicine R&D but leaves rhCollagen production and bioink supply in place.

Available on EDGAR 11/02/2026 - 04:30 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. appointed Eran Rotem, its Deputy Chief Executive Officer and Chief Financial Officer, as Chief Executive Officer effective November 2, 2026. He will continue as CFO, with compensation terms unchanged at this time. The Board determined Yehiel Tal would cease serving as CEO effective immediately; he resigned as Interim Chairman but will remain a Board member. These changes were made in connection with a cost-reduction plan designed to optimize operating expenses.

As part of the plan, CollPlant is discontinuing its regenerative medicine research and development activities. The plan does not affect production of recombinant human collagen (rhCollagen) at its facilities in Yessod Hama’ala and Rehovot, Israel. The company plans to continue producing and supplying rhCollagen and rhCollagen-based bioinks to its business partners, collaborators and customers.

Filing Explained

This 6-K is incorporated into CollPlant’s listed Form S-8 and F-3 registration statements from submission, adding its leadership and cost-reduction disclosures to those filings unless later reports supersede them.

Key Terms

regenerative medicine research and development, recombinant human collagen, bioinks

3 terms

regenerative medicine research and development technical

"discontinuing its regenerative medicine research and development activities"

recombinant human collagen technical

"production of recombinant human collagen (rhCollagen)"

Collagen produced by inserting human collagen genes into cells or microorganisms so they manufacture the same protein sequence found in people; the product is purified from those cultured cells rather than taken from animal tissue. It matters to investors because it is a scalable, standardized source of human-sequence collagen used in medical products (wound care, implants, cosmetics and drug delivery), and its production method affects manufacturing cost, regulatory review, intellectual property and market differentiation—like making a recipe in a factory instead of harvesting it from different farms.

bioinks technical

"rhCollagen-based bioinks"

Bioinks are printable formulations made from living cells mixed with supportive materials that allow 3D printers to build tissue-like structures layer by layer—think of them as cake batter with seeds that can be shaped into living tissue. They matter to investors because they are the core technology enabling applications like lab-grown tissue for drug testing, medical implants, and future organ fabrication, so advances or commercial adoption can drive growth, partnerships, intellectual property value, and regulatory risk/reward.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CEO of CLGN?

Eran Rotem was appointed Chief Executive Officer effective November 2, 2026. He will continue serving as Chief Financial Officer, and his compensation terms will remain unchanged at this time.

Is CollPlant stopping rhCollagen production?

No. The cost-reduction plan does not affect production of recombinant human collagen at the company’s facilities in Yessod Hama’ala and Rehovot, Israel. CollPlant plans to continue producing and supplying rhCollagen and rhCollagen-based bioinks to business partners, collaborators and customers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

This Form 6-K hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731, 333-292640 and 333-297347), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On November 2, 2026, the Board of Directors (the “Board”) of CollPlant Biotechnologies Ltd. (the “Company”) determined that Yehiel Tal will cease serving as Chief Executive Officer of the Company, effective immediately (the “Effective Date”). This determination was made in connection with a broader cost-reduction plan designed to optimize the Company's operating expenses. On the same date, the Board appointed Eran Rotem, the Company’s Deputy Chief Executive Officer and Chief Financial Officer, as Chief Executive Officer of the Company, effective as of the Effective Date. Mr. Rotem will continue to serve as the Company’s Chief Financial Officer and his compensation terms will remain unchanged at this time.

In connection with the foregoing, Mr. Tal resigned as Interim Chairman of the Board, effective as of the Effective Date, although he will continue to serve as a member of the Board. The terms of Mr. Tal’s separation, including any amounts payable to him in connection therewith, will be in accordance with his employment agreement, the Company’s Compensation Policy for Executive Officers and Directors and applicable law. The Board thanks Mr. Tal for his many years of service and his contributions to the Company.

As part of the cost reduction plan, the Company is discontinuing its regenerative medicine research and development activities. The plan does not affect the Company’s production of recombinant human collagen (rhCollagen), which is carried out at the Company’s facilities in Yessod Hama’ala and Rehovot, Israel. The Company plans to continue to produce and supply rhCollagen and rhCollagen-based bioinks to its business partners, collaborators and customers.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: November 2, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Chief Executive Officer and Chief Financial Officer

2